M D Anderson Cancer Center Prosate SPORE

通过这项申请，安德森癌症中心寻求为前列腺癌新孢子提供资金。在首席研究员Christopher J.Logothetis博士和联合首席研究员Timothy C.Thompson博士的领导下，M.D.安德森癌症中心前列腺癌孢子已经为翻译研究创建了一个稳定和动态的基础设施，致力于为局限性前列腺癌患者开发非病理性疗法；识别治疗反应的预测生物标记物；开发新的生物靶向治疗剂；以及将恶性前列腺癌的流行病学和分子信号特征联系起来。我们继续加强我们进行新颖和创新临床试验的能力，并相信我们的翻译研究团队开展的新研究项目将在临床实践中产生实质性进展和有意义的变化。 在目前的提案中，我们将我们的转化性研究目标定义为：(1)开发用于确定侵袭性前列腺癌的定量工具；(2)在原则临床试验中测试新型治疗药物；(3)开发用于识别对靶向治疗有反应的患者的预测生物标记物；以及(4)开发合理的联合治疗策略。 我们将通过识别和测试恶性前列腺癌的肥胖相关生物标记物，前列腺癌GLIPR1-ATM蛋白和一种新的配体导向的促凋亡多肽(BMTP-11)的临床测试，以及在晚期前列腺癌患者中进行两项假说驱动的临床试验，使用新型的成纤维细胞生长因子信号抑制剂(TKL 258)和联合Src抑制剂(达沙替尼)多西紫杉醇来实现这些翻译研究目标。 我们将通过5个研究项目(包括1个人口科学研究项目)、3个支持核心(行政、生物统计学和生物信息学以及标本)、动态发展研究计划和有效的职业发展计划来实现我们的目标。我们乐观地认为，通过将基础研究转化为临床实践，我们的研究努力将有助于减少这种毁灭性疾病的发病率、发病率和死亡率。

Through this application M. D. Anderson Cancer Center seeks funding for a new Prostate Cancer SPORE. Under the leadership of Dr. Christopher J. Logothetis, Principal Investigator, and Dr. Timothy C. Thompson, Co-Principal Investigator, who are recognized internationally for their research in prostate cancer, the M. D. Anderson Cancer Center Prostate SPORE has created a stable and dynamic infrastructure for translational research that works toward the development of non-morbid therapies for patients with localized prostate cancer; the identification of predictive biomarkers for therapeutic response; the development of new biologically targeted therapeutic agents; and the linkage of epidemiological and molecular signaling profiles for virulent prostate cancer. We continue to build on our capacity to conduct novel and innovative clinical trials and believe that new research projects conducted by our translational research team will yield substantial progress and meaningful changes in clinical practice. In the current proposal we define our translational research objectives as (1) development of quantitative tools for determination of aggressive prostate cancers; (2) testing of novel therapeutic agents in proof of principle clinical trials; (3) development of predictive biomarkers for identification of patients who will respond to targeted therapies; and (4) development of rational strategies for combination therapies. We will achieve these translational research objectives by identifying and testing obesity-related biomarkers for virulent prostate cancer, clinical testing of GLIPR1-ATM protein and a novel ligand-directed pro-apoptotic peptide (BMTP-11) for prostate cancer, and conducting two hypothesis-driven clinical trials with a novel FGF signaling inhibitor (TKl 258), and combination Src inhibitor (Dasatinib)+Docetaxel in patients with advanced prostate cancer. We will accomplish our goals through 5 research projects (including one population science research project), 3 support cores (Administrative, Biostatistics and Bioinformatics, and Specimen), a dynamic Developmental Research Program and an effective Career Development Program. We are optimistic that our research efforts will contribute to reductions in the incidence of, and morbidity and mortality from, this devastating disease by translating basic research into clinical practice.